Gp Medical, Inc.

Tsinghua University

Other

3f Therapeutics, Inc.

Xepmed, Inc.

Maxwell Sensors, Inc.

Glaukos Corporation

Reshape Medical, Inc.

Quantumcor, Inc

Evalve, Inc.

Intersect Partners, LLC

Evalva, Inc.

Onita Inc

Hosheng Tu

Hsing-Wen Sung

Kiran Sonaje

Yu-Hsin Lin

Hsiang-Fa Liang

Er-Yuan Chuang

Mei-Chin Chen

Ho-Ngoc Nguyen

Rodolfo C Quijano

Zi-Xian Liao

Ha Giang Thi Nguyen

Wallace Neil Hauck

Winston Z Ho

Yu-An Chang

Fang Yi Su

Andrew H Cragg

Samuel Victor Lichtenstein

Huang-Chien Liang

Hun-Chi Lin

Po-Wei Lee

Ko-Jie Chen

Shu-Fen Peng

David S Haffner

George B Wallace

Gregory T Smedley

Thomas W Burns

Thomas H Witzel

John A Osth

Min-Fan Chung

Pao-Hsien Chu

Morteza Gharib

Richard J Greff

Jonathan Kagan

Richard L Lindstrom

Barbara A Niksch

Than Nguyen

Stephen Sosnowski

Bobby K Purkait

Daniel H Duff

Jason Artof

Po-Yuan Cheng

Wen-Hsiang Chang

Shu-Wha Lin

Li-Wen Hsu

Rodolfo C Quijana

Er-Yuan Chung

Cherng-Jyh Ke

Robert J Socci, Jr

James Peter Anduiza

Teng-Nan Lin

I-Shing Yu

Hung-Kun Hsu

Chin-Tsung Huang

Ting-Fan Yang

Peter Y Tu

Stephen A Sosnowski

Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into Schlemm's canal as well as preventing the walls of Schlemm's canal from closing the outlet of the stents. The applicators can be steerable so as to make implantation easier. Additionally, the applicators can be configured to hold a plurality of stents so that multiple stents can be implanted through one incision without removing the applicator from the incision between serial implantations.

Devices and methods for glaucoma treatment

Surgical methods and related medical devices for treating glaucoma are disclosed. The method comprises trabecular bypass surgery, which involves bypassing diseased trabecular meshwork with the use of a stent implant. The stent implant is inserted into an opening created in the trabecular meshwork by a piercing member that is slidably advanceable through the lumen of the stent implant for supporting the implant insertion. The stent implant is positioned through the trabecular meshwork so that an inlet end of the stent implant is exposed to the anterior chamber of the eye and an outlet end is positioned into fluid collection channels at about an exterior surface of the trabecular meshwork or up to the level of aqueous veins.

Implant delivery system and methods thereof for treating ocular disorders

A gastric space filler device for treating obesity in a patient by reducing the stomach volume comprising an inflatable space filler and a safety element secured to the space filler, wherein the safety element yields a noticeable signal for causing removal of the space filler.

Intragastric space filler

The invention discloses use of a pharmaceutical composition for slow-release delivery of a bioactive agent, comprising mixing the bioactive agent with a partially hydrophobic chitosan solution at a low pH and delivering the hydrogel at a physiological pH to transform the hydrogel to a solid complex for releasing the bioactive agent. The partially hydrophobic chitosan is characterized by presence of alternating charges of protonated amine groups and hydrophobic side groups.

Pharmaceutical composition of nanoparticles

The invention discloses a pharmaceutical composition of pH-sensitive liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising a proton-releasing photosensitive compound that releases protons upon photolysis, wherein the compound is in vesicles of the liposomes. A light or UV light is provided to induce the photosensitive compound to release the protons, thus the released protons causing the pH-sensitive liposome to decompose.

The invention discloses a pharmaceutical composition of nanoparticles consisting of chitosan, a negatively charged substrate, and at least one bioactive agent that is encapsulated within cucurbiturils for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA, RNA or bioactive agent characterized with a positive surface charge and their enhanced efficiency for gene delivery and bioactive agent delivery.

Nanoparticles for delivery of bioactive agents

The invention discloses the nanoparticles composed of chitosan, poly-&#x3b3;-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Nanoparticles for protein drug delivery

The invention discloses a pharmaceutical composition of multifunctional core-shell nanoparticles, each nanoparticle comprising: a core portion comprised of hydrophobic poly(D,L-lactic-co-glycolic acid) (PLGA) and a detection-enhancing substance, and a shell portion comprised of positively charged chitosan adapted to cause no aggregation of nanoparticles due to electrostatic repulsion between the positively charged nanoparticles. In one embodiment, the detection-enhancing substance includes SPIO, a quantum dot, a fluorescent quantum dot, a bubble, an air bubble, and the like.

The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.

Growing community of inventors

Newport Beach, CA, United States of America

Hosheng Tu